Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.90 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.82 |
| ▸ | NPC1 | O15118 | 1/20 | 0.82 |
| ▸ | RECQL | P46063 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | ATM | Q13315 | 1/20 | 0.82 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.82 |
| ▸ | MAOB | P27338 | 3/20 | 0.80 |
| ▸ | MAOA | P21397 | 1/20 | 0.80 |
| ▸ | APP | P05067 | 4/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31233034 | 1.00 | ABCG2 (1.00) | ABCG2NR1H4LMNAMAPTNPC1 | |
| SCHEMBL5138658 | 1.00 | ABCG2 (1.00) | ABCG2NR1H4LMNAMAPTNPC1 | |
| SCHEMBL23933032 | 0.96 | ABCG2 (0.92) | ABCG2NR1H4LMNAMAPTNPC1 | |
| SCHEMBL25191387 | 0.96 | ABCG2 (0.92) | ABCG2NR1H4LMNAMAPTNPC1 | |
| SCHEMBL4052514 | 0.95 | ABCG2 (1.00) | ABCG2NR1H4LMNAMAPTNPC1 | |
| SCHEMBL30384231 | 0.95 | ABCG2 (1.00) | ABCG2NR1H4LMNAMAPTNPC1 | |
| SCHEMBL4052509 | 0.95 | ABCG2 (1.00) | ABCG2NR1H4LMNAMAPTNPC1 | |
| SCHEMBL30384486 | 0.95 | ABCG2 (1.00) | ABCG2NR1H4LMNAMAPTNPC1 | |
| SCHEMBL25185009 | 0.94 | ABCG2 (0.90) | ABCG2NR1H4LMNAMAPTNPC1 | |
| SCHEMBL21527675 | 0.94 | ABCG2 (0.90) | ABCG2NR1H4LMNAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562803-B1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2025-10-15 | — | — | EP | claimed |
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-11-07 | — | — | US | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2021-11-25 | — | — | US | disclosed |
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-11-07 | — | — | US | disclosed |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | ABCG2 5/4885NR1H4 32/4885LMNA 4191/4885 |
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | NOTCH1, DNER, NOTCH2 | ABCG2 2354/4885NR1H4 1212/4885LMNA 2993/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | ABCG2 1606/4885NR1H4 3875/4885LMNA 1180/4885 |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | ABCG2 3643/4885NR1H4 46/4885LMNA 2177/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885NR1H4 2983/4885LMNA 1817/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885NR1H4 2983/4885LMNA 1817/4885 |
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | NOTCH1, DNER, NOTCH2 | ABCG2 2354/4885NR1H4 1212/4885LMNA 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.